Moderna said Monday that its COVID-19 vaccine is able to generate a strong immune response in children ages 6 to 11, citing a new study. The company said that an interim analysis of data showed a “robust neutralizing antibody response” after two shots of its mRNA-1273 vaccine were administered at a 50 microgram dose level, or half the dosage of the vaccine used in adults, to children in this age group. The study, called KidCOVE, evaluated the safety, tolerability, adverse reactions, and effectiveness of two lower doses of the Moderna vaccine given to healthy children four weeks apart, according to the company. In this randomized, placebo-controlled study, the participants were divided into three age groups, including 4,753 children aged 6 to 11. Participants were given either the vaccine or a placebo. Moderna said its vaccine was well tolerated with a safety and tolerability profile generally consistent with its study of …